TNFRSF1A and acute respiratory distress syndrome: GSK has developed two inhalable anti-TNFR1 VH domain antibodies for selective antagonism of TNF in the lung interstitium for acute respiratory distress syndrome (ARDS)/acute lung inflammation (ALI).